Pasar al contenido principal

INTERACCION DEL SISTEMA ENDOCANNABINOIDE PERIFERICO CON LAS AFERENCIAS VAGALES EN EL CONTEXTO DE LA MEJORA COGNITIVA Y SU EVALUACION EN MODELOS DE ENVEJECIMIENTO

PID2021-123482OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT POMPEU FABRA CCT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes

  • Vázquez-Oliver, Anna
  • Pérez-García, Silvia
  • Romero-Pérez, Rafael
  • Pizarro Lozano, Ma. Nieves
  • Galarraga-Shinin, Diana
  • Molina-Porcel, Laura
  • Torre Fornell, Rafael de la
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
INTRODUCTION: Down syndrome (DS) is the most common genetic cause of intellectual disability, affecting cognitive function and increasing the risk of early-onset Alzheimer's disease (AD). The endocannabinoid system may serve as a therapeutic target for cognitive deficits by inhibiting cannabinoid type-1 receptor (CB1R) function. METHODS: CB1R expression was analyzed in the hippocampi of aged DS-associated AD (DSAD) individuals and middle-aged Ts65Dn mice. Long-term oral treatment with the CB1R antagonist rimonabant was used to assess its effects on memory and neuroinflammation in the Ts65Dn mouse model of DS. RESULTS: CB1R expression was significantly increased in both aged DSAD subjects (specifically in the dentate gyrus and CA2 posterior hippocampal subregions) and Ts65Dn mice. Long-term rimonabant treatment improved memory performance, normalized microglial morphology, and reduced plasma inflammatory markers in trisomic mice without preventing neuron decline. DISCUSSION: These findings suggest that sustained CB1R inhibition may enhance cognitive function by modulating neuroinflammation, highlighting its therapeutic potential for cognitive impairments in DS. Highlights: Cannabinoid type-1 receptor (CB1R) expression is increased in the posterior hippocampus of aged Down syndrome (DS) subjects and Ts65Dn mice. Long-term rimonabant treatment enhances memory in middle-aged Ts65Dn mice. CB1R inhibition shifts neuroinflammatory features in Ts65Dn mice. CB1R inhibition does not halt noradrenergic/cholinergic neurodegeneration in Ts65Dn. CB1R inhibition presents potential for memory improvement in DS-related deficits., Ministerio de Ciencia, Innovación y Universidades, Grant/Award Numbers:RTI2018-099282-B-I00, PID2021-123482OB-I00-/MICIN/AEI/10.13039/501100011033/FEDER,PID2020- 120029GB-I00/MICIN/AEI/10.13039/501100011033; Fondation Jérôme Lejeune, Grant/Award Numbers:1896_GRT-2019B, #2416_GRT-2024B; Bright Focus foundation, Grant/Award Number:CA2018010; Ministerio de Sanidad, Servicios Sociales e Igualdad, Grant/Award Number:RD16/0017/0020; Departament de Recerca i Universitats, Generalitat de Catalunya,Grant/Award Number: 2017SGR-669 Departament d'Economia i Coneixement, Generalitat de Catalunya, Grant/Award Number: 2017SGR-138; Institució Catalana de Recerca i Estudis Avançats, ICREA-Acadèmia2021
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Amyloid β-peptide causes the permanent activation of CaMKIIα through its oxidation

  • Picón-Pagès, Pol
  • Fanlo-Ucar, Hugo
  • Herrera-Fernández, Víctor
  • Ausellé Bosch, Sira
  • Galera López, Lorena, 1993-
  • Gutiérrez, Daniela A.
  • Ozaita Mintegui, Andrés, 1969-
  • Álvarez, Alejandra R.
  • Oliva Miguel, Baldomero
  • Muñoz López, Francisco José, 1964-
Alzheimer's disease (AD) is characterised by the presence of extracellular amyloid plaques in the brain. They are composed of aggregated amyloid beta-peptide (Aβ) misfolded into beta-sheets which are the cause of the AD memory impairment and dementia. Memory depends on the hippocampal formation and maintenance of synapses by long-term potentiation (LTP), whose main steps are the activation of NMDA receptors, the phosphorylation of CaMKIIα and the nuclear translocation of the transcription factor CREB. It is known that Aβ oligomers (oAβ) induce synaptic loss and impair the formation of new synapses. Here, we have studied the effects of oAβ on CaMKIIα. We found that oAβ produce reactive oxygen species (ROS), that induce CaMKIIα oxidation in human neuroblastoma cells as we assayed by western blot and immunofluorescence. Moreover, this oxidized isoform is significantly present in brain samples from AD patients. We found that the oxidized CaMKIIα is active independently of the binding to calcium/calmodulin, and that CaMKIIα phosphorylation is mutually exclusive with CaMKIIα oxidation as revealed by immunoprecipitation and western blot. An in silico modelling of the enzyme was also performed to demonstrate that oxidation induces an activated state of CaMKIIα. In brains from AD transgenic models of mice and in primary cultures of murine hippocampal neurons, we demonstrated that the oxidation of CaMKIIα induces the phosphorylation of CREB and its translocation to the nucleus to promote the transcription of ARC and BDNF. Our data suggests that CaMKIIα oxidation would be a pro-survival mechanism that is triggered when a noxious stimulus challenges neurons as do oAβ., This work was supported by the Spanish Ministry of Science and Innovation and Agencia Estatal de Investigación plus FEDER Funds through grants PID2020-117691RB-I00/AEI/10.13039/501100011033 (F.J.M.), SAF2017-83372-R (F.J.M.), BIO 2020-113203RB (B.O.) and PID2021-123482OB-I00 (A.O.). This work was also funded by the “María de Maetzu Programme” for Units of Excellence in R&D and the MM-MELIS intercollaborative projects (award CEX2018-000792-M/IPEP-MM2020-5). Funding for this project was also from the Comisión Nacional de Investigación Científica y Tecnológica-Chile: Fondecyt 12011668 (to A.R.Á.) and Millennium Science Initiative Program—ICN09_016/ICN 2021_045 (to A.R.Á.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Amyloid β-peptide causes the permanent activation of CaMKIIα through its oxidation

  • Picón-Pagès, Pol
  • Fanlo-Ucar, Hugo
  • Herrera-Fernández, Víctor
  • Ausellé Bosch, Sira
  • Galera López, Lorena, 1993-
  • Gutiérrez, Daniela A.
  • Ozaita Mintegui, Andrés, 1969-
  • Álvarez, Alejandra R.
  • Oliva Miguel, Baldomero
  • Muñoz López, Francisco José, 1964-
Alzheimer's disease (AD) is characterised by the presence of extracellular amyloid plaques in the brain. They are composed of aggregated amyloid beta-peptide (Aβ) misfolded into beta-sheets which are the cause of the AD memory impairment and dementia. Memory depends on the hippocampal formation and maintenance of synapses by long-term potentiation (LTP), whose main steps are the activation of NMDA receptors, the phosphorylation of CaMKIIα and the nuclear translocation of the transcription factor CREB. It is known that Aβ oligomers (oAβ) induce synaptic loss and impair the formation of new synapses. Here, we have studied the effects of oAβ on CaMKIIα. We found that oAβ produce reactive oxygen species (ROS), that induce CaMKIIα oxidation in human neuroblastoma cells as we assayed by western blot and immunofluorescence. Moreover, this oxidized isoform is significantly present in brain samples from AD patients. We found that the oxidized CaMKIIα is active independently of the binding to calcium/calmodulin, and that CaMKIIα phosphorylation is mutually exclusive with CaMKIIα oxidation as revealed by immunoprecipitation and western blot. An in silico modelling of the enzyme was also performed to demonstrate that oxidation induces an activated state of CaMKIIα. In brains from AD transgenic models of mice and in primary cultures of murine hippocampal neurons, we demonstrated that the oxidation of CaMKIIα induces the phosphorylation of CREB and its translocation to the nucleus to promote the transcription of ARC and BDNF. Our data suggests that CaMKIIα oxidation would be a pro-survival mechanism that is triggered when a noxious stimulus challenges neurons as do oAβ., This work was supported by the Spanish Ministry of Science and Innovation and Agencia Estatal de Investigación plus FEDER Funds through grants PID2020-117691RB-I00/AEI/10.13039/501100011033 (F.J.M.), SAF2017-83372-R (F.J.M.), BIO 2020-113203RB (B.O.) and PID2021-123482OB-I00 (A.O.). This work was also funded by the “María de Maetzu Programme” for Units of Excellence in R&D and the MM-MELIS intercollaborative projects (award CEX2018-000792-M/IPEP-MM2020-5). Funding for this project was also from the Comisión Nacional de Investigación Científica y Tecnológica-Chile: Fondecyt 12011668 (to A.R.Á.) and Millennium Science Initiative Program—ICN09_016/ICN 2021_045 (to A.R.Á.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Targeting dysregulated CB1 receptors in a down syndrome mouse model improves neurological outcomes

  • Vázquez-Oliver, Anna
  • Pérez-García, Silvia
  • Romero-Pérez, Rafael
  • Pizarro Lozano, Ma. Nieves
  • Galarraga-Shinin, Diana
  • Molina-Porcel, Laura
  • Torre Fornell, Rafael de la
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
INTRODUCTION: Down syndrome (DS) is the most common genetic cause of intellectual disability, affecting cognitive function and increasing the risk of early-onset Alzheimer's disease (AD). The endocannabinoid system may serve as a therapeutic target for cognitive deficits by inhibiting cannabinoid type-1 receptor (CB1R) function. METHODS: CB1R expression was analyzed in the hippocampi of aged DS-associated AD (DSAD) individuals and middle-aged Ts65Dn mice. Long-term oral treatment with the CB1R antagonist rimonabant was used to assess its effects on memory and neuroinflammation in the Ts65Dn mouse model of DS. RESULTS: CB1R expression was significantly increased in both aged DSAD subjects (specifically in the dentate gyrus and CA2 posterior hippocampal subregions) and Ts65Dn mice. Long-term rimonabant treatment improved memory performance, normalized microglial morphology, and reduced plasma inflammatory markers in trisomic mice without preventing neuron decline. DISCUSSION: These findings suggest that sustained CB1R inhibition may enhance cognitive function by modulating neuroinflammation, highlighting its therapeutic potential for cognitive impairments in DS. Highlights: Cannabinoid type-1 receptor (CB1R) expression is increased in the posterior hippocampus of aged Down syndrome (DS) subjects and Ts65Dn mice. Long-term rimonabant treatment enhances memory in middle-aged Ts65Dn mice. CB1R inhibition shifts neuroinflammatory features in Ts65Dn mice. CB1R inhibition does not halt noradrenergic/cholinergic neurodegeneration in Ts65Dn. CB1R inhibition presents potential for memory improvement in DS-related deficits., Ministerio de Ciencia, Innovación y Universidades, Grant/Award Numbers:RTI2018-099282-B-I00, PID2021-123482OB-I00-/MICIN/AEI/10.13039/501100011033/FEDER,PID2020- 120029GB-I00/MICIN/AEI/10.13039/501100011033; Fondation Jérôme Lejeune, Grant/Award Numbers:1896_GRT-2019B, #2416_GRT-2024B; Bright Focus foundation, Grant/Award Number:CA2018010; Ministerio de Sanidad, Servicios Sociales e Igualdad, Grant/Award Number:RD16/0017/0020; Departament de Recerca i Universitats, Generalitat de Catalunya,Grant/Award Number: 2017SGR-669 Departament d'Economia i Coneixement, Generalitat de Catalunya, Grant/Award Number: 2017SGR-138; Institució Catalana de Recerca i Estudis Avançats, ICREA-Acadèmia2021